Novo Nordisk (NVO) reported Wednesday Q4 earnings of 6.34 Danish kroner ($0.88) per diluted share, up from 4.91 kroner a year earlier.
Analysts polled by FactSet expected 5.96 kroner.
Sales for the quarter ended Dec. 31 were 85.68 billion kroner, up from 65.86 billion kroner a year earlier.
Analysts polled by FactSet expected 80.7 billion kroner.
For 2025, the company expects sales growth at constant exchange rates of 16% to 24%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。